focus -WSS

focus

author：hotspot 2025-09-28 09:56:39 - browse：612

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： 3 medical device trends to watch in 2024

focus

hotspot

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Asbestos, a deadly carcinogen, banned by EPA

Leading voice in opioid treatment defends methadone clinic system

SCOTUS questions limit to govt efforts to fight misinformation

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Readout Newsletter: Bluebird, CVS, Contineum

entertainment

focus

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

GSK Flovent asthma inhalers replaced by authorized generics

Walensky prepares to leave CDC — and Congress — behind

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Supreme Court strikes down use of affirmative action

App could help diagnose ear infections more accurately — and at home

23andMe had bad news about my health. I wish a person had delivered it

U.K. researchers warn about biases in medical devices, algorithms

Bright Health sells Medicare Advantage business to Molina

Leading voice in opioid treatment defends methadone clinic system

hotspot

Health AI adoption puts security, privacy startups on investors' radar

Feng Zhang, Grail founder join forces on new gene editing startup

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Leading voice in opioid treatment defends methadone clinic system

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Feng Zhang CRISPR delivery startup lays off quarter of staff

focus

hotspot

knowledge

explore